Chardan Capital Raises Taysha Gene Therapies (NASDAQ:TSHA) Price Target to $10.00

Taysha Gene Therapies (NASDAQ:TSHA) had its target price raised by Chardan Capital from $9.00 to $10.00 in a report published on Tuesday morning,Benzinga reports. Chardan Capital currently has a buy rating on the stock.

Several other research analysts have also recently issued reports on TSHA. Cantor Fitzgerald reiterated an “overweight” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Monday, April 28th. Citigroup reiterated an “outperform” rating on shares of Taysha Gene Therapies in a research report on Thursday, May 29th. Canaccord Genuity Group increased their price objective on Taysha Gene Therapies from $9.00 to $11.00 and gave the stock a “buy” rating in a research report on Tuesday, June 3rd. Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, July 1st. Finally, Bank of America assumed coverage on Taysha Gene Therapies in a research report on Friday, July 11th. They issued a “buy” rating and a $8.00 price objective for the company. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, Taysha Gene Therapies currently has an average rating of “Buy” and a consensus target price of $8.33.

Taysha Gene Therapies Price Performance

Shares of NASDAQ TSHA opened at $2.91 on Tuesday. The company has a debt-to-equity ratio of 0.77, a current ratio of 5.35 and a quick ratio of 5.35. The stock has a fifty day moving average price of $2.59 and a 200 day moving average price of $2.09. Taysha Gene Therapies has a 1-year low of $1.05 and a 1-year high of $3.31. The company has a market cap of $624.66 million, a PE ratio of -8.56 and a beta of 0.98.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.02). The company had revenue of $1.99 million for the quarter, compared to analyst estimates of $1.61 million. Taysha Gene Therapies had a negative return on equity of 104.93% and a negative net margin of 1,201.08%. Sell-side analysts forecast that Taysha Gene Therapies will post -0.35 EPS for the current year.

Insider Buying and Selling at Taysha Gene Therapies

In other news, major shareholder Paul B. Manning purchased 750,000 shares of the company’s stock in a transaction dated Friday, May 30th. The stock was acquired at an average price of $2.75 per share, for a total transaction of $2,062,500.00. Following the completion of the transaction, the insider directly owned 2,841,704 shares in the company, valued at $7,814,686. This represents a 35.86% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. 3.78% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Ground Swell Capital LLC purchased a new position in shares of Taysha Gene Therapies in the fourth quarter valued at $25,000. May Hill Capital LLC purchased a new position in shares of Taysha Gene Therapies in the second quarter valued at $37,000. Hsbc Holdings PLC increased its position in shares of Taysha Gene Therapies by 65.6% in the fourth quarter. Hsbc Holdings PLC now owns 20,391 shares of the company’s stock valued at $36,000 after buying an additional 8,076 shares in the last quarter. Prudential Financial Inc. increased its position in shares of Taysha Gene Therapies by 50.5% in the second quarter. Prudential Financial Inc. now owns 22,790 shares of the company’s stock valued at $53,000 after buying an additional 7,650 shares in the last quarter. Finally, Ameriprise Financial Inc. purchased a new stake in Taysha Gene Therapies during the 4th quarter worth about $40,000. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.